Form 4: Xeris Biopharma Holdings CEO Acquires Shares and Stock Appreciation Rights
SEC Form 4 Filing
CEO John Patrick Shannon Jr. reports acquisition of shares and stock appreciation rights in Xeris Biopharma Holdings.
Summary
- On January 31, 2025, John Patrick Shannon Jr., CEO of Xeris Biopharma Holdings, reported transactions involving the company's stock.
- 110,750 shares were withheld by the issuer to cover income tax obligations related to vested restricted stock units at a price of $3.56.
- Shannon acquired 800,000 shares through a restricted stock unit grant under the 2018 Stock Option and Incentive Plan, vesting annually over three years.
- He also acquired 600,000 stock appreciation rights (SARs) under the same plan, vesting fully on March 2, 2027, and settled in cash upon exercise.
- Following these transactions, Shannon directly owns 2,687,118 shares of Xeris Biopharma Holdings.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The CEO acquiring shares and stock appreciation rights suggests confidence in the company's future, but it's a routine transaction.
Positives
- The CEO's acquisition of shares and stock appreciation rights demonstrates confidence in the company's future.
- The vesting schedule of the restricted stock units and SARs incentivizes long-term performance.
Future Outlook
The restricted stock units vest annually over three years, and the stock appreciation rights vest in full on March 2, 2027, subject to continued service with the company.
Industry Context
Insider transactions are closely monitored as they can provide insights into management's perspective on the company's prospects. This Form 4 filing is a routine disclosure required by the SEC.
Comparison to Industry Standards
- Stock-based compensation, including restricted stock units and stock appreciation rights, is a common practice among publicly traded companies, particularly in the biopharmaceutical industry, to align management's interests with those of shareholders.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation plans.
- The vesting schedules and terms of these grants are generally comparable to industry standards.
Stakeholder Impact
- The CEO's increased stake in the company could positively influence shareholder confidence.
- Employees may view the equity grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/31/2025 | Date of transaction: shares withheld for tax obligations, acquisition of restricted stock units and stock appreciation rights. |
| 02/03/2025 | Date of signature by Attorney-in-Fact. |
| 03/02/2027 | Vesting date for the stock appreciation rights. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.